Leukeran (Chlorambucil)

Chlorambucil works by adding alkyl groups to DNA bases, creating cross‑links that block DNA replication and transcription. This damage triggers cell‑cycle arrest and programmed cell death, especially in rapidly dividing cancer cells of the lymphoid system.

The dosage of Leukeran is individualized and determined by the prescribing oncologist based on the specific cancer type, disease stage, patient weight, renal and hepatic function, and blood count parameters. Patients should follow the exact regimen provided by their healthcare professional.

Safety of chlorambucil in pregnancy and lactation has not been established. It is generally contraindicated because it may cause fetal harm or be excreted in breast milk. Use only if the potential benefit justifies the potential risk, and discuss alternatives with a specialist.

To order Leukeran, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and necessary import documentation.

Leukeran (chlorambucil) belongs to the alkylating agent class, similar to cyclophosphamide. Compared with cyclophosphamide, chlorambucil has a longer half‑life and is administered orally, offering convenience, but may have a higher incidence of certain hematologic toxicities. Choice depends on disease protocol and patient tolerance.

Leukeran tablets should be stored at ambient temperature, below 25 °C, in the original blister pack to protect from moisture and light. Keep out of reach of children and do not use if the packaging is damaged or the tablets appear discolored.

Leukeran is taken orally with a full glass of water, preferably on an empty stomach unless directed otherwise by the prescriber. Swallow the tablet whole; do not crush or chew it, as this could affect absorption and increase the risk of gastrointestinal irritation.

Serious risks include profound myelosuppression leading to severe infection, bleeding, or anemia; secondary malignancies such as therapy‑related leukemia; hepatic toxicity; and rare pulmonary fibrosis. Patients should report fever, unusual bruising, persistent cough, or jaundice to their physician promptly.

Leukeran is contraindicated in individuals with known hypersensitivity to chlorambucil or other alkylating agents, those with severe bone‑marrow suppression, uncontrolled infections, or significant hepatic impairment. Caution is also advised for patients with pre‑existing lung disease or a history of secondary cancers.